Hendrik-Jan Thibaut

List of Publications by Year
in descending order

45 papers	3,583 citations	236612 25 h-index	214527 47 g-index
59 all docs	59 docs citations	59 times ranked	6562 citing authors

#	Article	IF	Citations
1	Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings. Biomedicines, 2022, 10, 268.	1.4	2
2	MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters. Frontiers in Immunology, 2022, 13, 845969.	2.2	16
3	Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Molecular Therapy - Methods and Clinical Development, 2022, 25, 215-224.	1.8	5
4	Use of Micro-Computed Tomography to Visualize and Quantify COVID-19 Efficiency in Free-Breathing Hamsters. Methods in Molecular Biology, 2022, 2410, 177-192.	0.4	5
5	High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium. Viruses, 2022, 14, 1257.	1.5	7
6	A High-Throughput Yellow Fever Neutralization Assay. Microbiology Spectrum, 2022, 10, .	1.2	8
7	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. IScience, 2022, 25, 104705.	1.9	8
8	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nature Genetics, 2021, 53, 435-444.	9.4	162
9	The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. PLoS Pathogens, 2021, 17, e1009500.	2.1	91
10	enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9. Molecular Therapy, 2021, 29, 208-224.	3.7	8
11	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature, 2021, 590, 320-325.	13.7	148
12	An affinity-enhanced, broadly neutralizing heavy chainâ€“only antibody protects against SARS-CoV-2 infection in animal models. Science Translational Medicine, 2021, 13, eabi7826.	5.8	41
13	Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. Emerging Microbes and Infections, 2021, 10, 2279-2290.	3.0	6
14	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2â^'infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26955-26965.	3.3	240
15	Animal models for COVID-19. Nature, 2020, 586, 509-515.	13.7	705
16	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nature Communications, 2020, 11, 5838.	5.8	225
17	Identification of the Cell-Surface Protease ADAM9 as an Entry Factor for Encephalomyocarditis Virus. MBio, 2019, 10, .	1.8	15
18	Bypassing pan-enterovirus host factor PLA2G16. Nature Communications, 2019, 10, 3171.	5.8	31

#	Article	IF	Citations
19	Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence. Emerging Microbes and Infections, 2019, 8, 1076-1085.	3.0	10
20	Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathogens, 2019, 15, e1007760.	2.1	26
21	Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerging Microbes and Infections, 2019, 8, 1734-1746.	3.0	18
22	The life cycle of non-polio enteroviruses and how to target it. Nature Reviews Microbiology, 2018, 16, 368-381.	13.6	275
23	Role of enhanced receptor engagement in the evolution of a pandemic acute hemorrhagic conjunctivitis virus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 397-402.	3.3	43
24	PLA2G16 represents a switch between entry and clearance of Picornaviridae. Nature, 2017, 541, 412-416.	13.7	168
25	Toward antiviral therapy/prophylaxis for rhinovirusâ€induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies. Reviews in Medical Virology, 2016, 26, 21-33.	3.9	22
26	Hydantoin: The mechanism of its inÂvitro anti-enterovirus activity revisited. Antiviral Research, 2016, 133, 106-109.	1.9	10
27	9-Norbornyl-6-chloropurine (NCP) induces cell death through GSH depletion-associated ER stress and mitochondrial dysfunction. Free Radical Biology and Medicine, 2016, 97, 223-235.	1.3	20
28	Enterovirus D68 receptor requirements unveiled by haploid genetics. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1399-1404.	3.3	86
29	Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP. Antiviral Research, 2015, 117, 110-114.	1.9	59
30	Sialic acid-dependent cell entry of human enterovirus D68. Nature Communications, 2015, 6, 8865.	5.8	101
31	Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein. Cell Reports, 2015, 10, 600-615.	2.9	201
32	The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. European Heart Journal, 2015, 36, 2909-2919.	1.0	95
33	Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrobial Agents and Chemotherapy, 2015, 59, 7782-7785.	1.4	54
34	Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis. PLoS Pathogens, 2014, 10, e1004039.	2.1	37
35	H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. Antiviral Research, 2014, 110, 1-9.	1.9	12
36	Fitness and Virulence of a Coxsackievirus Mutant That Can Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III Beta. Journal of Virology, 2014, 88, 3048-3051.	1.5	7

#	Article	IF	Citations
37	Molecular Biology and Inhibitors of Hepatitis A Virus. Medicinal Research Reviews, 2014, 34, 895-917.	5.0	31
38	A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIÎ². Antimicrobial Agents and Chemotherapy, 2013, 57, 4971-4981.	1.4	96
39	Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C. Antimicrobial Agents and Chemotherapy, 2013, 57, 1952-1956.	1.4	81
40	Efficient synthesis and anti-enteroviral activity of 9-arylpurines. European Journal of Medicinal Chemistry, 2012, 49, 279-288.	2.6	21
41	Combating enterovirus replication: State-of-the-art on antiviral research. Biochemical Pharmacology, 2012, 83, 185-192.	2.0	133
42	Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Research, 2011, 90, 213-217.	1.9	45
43	9-Arylpurines as a Novel Class of Enterovirus Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 316-324.	2.9	28
44	Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307. Antimicrobial Agents and Chemotherapy, 2009, 53, 1850-1857.	1.4	68
45	Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4â€induced pancreatitis. Journal of Pathology, 2009, 217, 633-641.	2.1	14